Welcome to our dedicated page for RESMED SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on RESMED's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into RESMED's regulatory disclosures and financial reporting.
Form 4 Overview – ResMed Inc. (RMD)
Chief Financial Officer Brett Sandercock reported a series of option exercises and an open-market sale on 1 July 2025 under a pre-arranged Rule 10b5-1 trading plan dated 19 Feb 2025.
- Options exercised: 2,883 options (strike $101.64) converted into common shares. These options were granted 11 Nov 2019 and expire 14 Nov 2025.
- Shares sold: 3,883 common shares disposed at an average price of $256.99, generating gross proceeds of roughly $1.0 million.
- Net ownership change: Holding declined from 87,249 to 84,283 shares, a reduction of 2,966 shares (≈3.4% of his previously reported direct stake).
- Remaining equity exposure: Sandercock still owns 84,283 common shares and 8,000 vested, unexercised options, maintaining significant alignment with shareholders.
The transaction appears routine—driven by option maturity and executed under a 10b5-1 plan—but the net sale may be interpreted as mildly bearish sentiment or personal liquidity management. The limited magnitude relative to total holdings lessens market impact, yet investors often track C-suite sales as potential leading indicators.